Dr. Druker, who was instrumental in the development of imatinib, highlighted the hurdles he faced in bringing the tyrosine-kinase inhibitor to market, particularly the skepticism from others in the field who were sure that a single-agent therapy for cancer would never work.
Carl H. June, MD, of the University of Pennsylvania, accepted the 2017 David A. Karnofsky Memorial Award and Lecture on June 3, an honor bestowed for his pioneering work on engineering T cells in targeted cancer therapy.
In contrast to more common cancers, some sarcoma subsets are fairly rare and standard treatments have not been established. However, for each sarcoma type discussed, strategies are being developed with the aim of improving outcomes for patients with sarcoma.
Both nivolumab alone and in combination with ipilimumab resulted in a promising disease control rate in patients with relapsing malignant pleural mesothelioma (MPM), according to the results of Abstract LBA8507.
The EGFR tyrosine-kinase inhibitor gefitinib appears to offer a disease-free survival benefit over vinorelbine/cisplatin as adjuvant therapy in patients with non–small cell lung cancer with EGFR-activating mutation.
ASCO’s recommendations and criteria to improve the development, implementation, and analysis of oncology pathways are first steps in managing enhancements to patient care while proving their benefit at the patient and societal levels.
Multiple studies have found that people age 65 and older are underrepresented in both cancer registration trials and the National Cancer Institute’s National Clinical Trials Network (NCTN) clinical trials, with only modest improvement over time.
Data from two phase II studies, the CheckMate 204 trial and the Anti-PD1 Brain Collaboration trial, lend support to combined use of nivolumab and ipilimumab to yield responses in melanoma that has metastasized to the brain.